Contact
searchSearch
HMP Global

CMSC Annual Meeting
CMSC Annual Meeting
Conference Coverage
Real-World Data May Show Lower Relapse Rates With Ofatumumab Compared to Ocrelizumab in MS Patients
06/03/2025
Hannah Musick
Real-world data show ofatumumab significantly reduces relapse rates compared to ocrelizumab in patients with relapsing multiple sclerosis, including those who are treatment-naïve.
Real-world data show ofatumumab significantly reduces relapse rates compared to ocrelizumab in patients with relapsing multiple sclerosis, including those who are treatment-naïve.
Real-world data show ofatumumab...
06/03/2025
First Report Managed Care
Conference Coverage
Exploring Patient Portal Messaging in MS Care: Value, Utilization, and Burnout Implications
06/03/2025
Juliet Gallagher
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become...
06/03/2025
First Report Managed Care
Conference Coverage
11-Year Data Support Sustained Efficacy and Safety of Ocrelizumab in MS
06/02/2025
Juliet Gallagher
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers...
06/02/2025
First Report Managed Care
Conference Coverage
TMS Shows Promise in Improving Cognitive Processing Speed in Patients With MS
06/02/2025
Hannah Musick
Transcranial magnetic stimulation may significantly improve processing speed in individuals with multiple sclerosis, suggesting potential for managing cognitive symptoms.
Transcranial magnetic stimulation may significantly improve processing speed in individuals with multiple sclerosis, suggesting potential for managing cognitive symptoms.
Transcranial magnetic...
06/02/2025
First Report Managed Care
Conference Coverage
Cladribine Tablets Show Strong Results in Patients With MS Switching from Injectable Therapies
05/29/2025
Grace Taylor, MS, MA
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that...
05/29/2025
First Report Managed Care
Conference Coverage
Study Identifies Key Barriers and Potential Solutions to Boost Black Patient Participation in MS Trials
05/29/2025
Hannah Musick
A new study presented at CMSC 2025 identifies key barriers to Black patient participation in MS clinical trials and outlines targeted strategies to improve inclusion and equity in research.
A new study presented at CMSC 2025 identifies key barriers to Black patient participation in MS clinical trials and outlines targeted strategies to improve inclusion and equity in research.
A new study presented at CMSC...
05/29/2025
First Report Managed Care
Conference Coverage
Serum Biomarker Test May Track Disease Activity in Common MS Scenarios
05/28/2025
Hannah Musick
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease...
05/28/2025
First Report Managed Care
Conference Coverage
DMT Exposure Tied to Greater Health Care Utilization, No Mobility Benefit in Matched Patients With MS
05/28/2025
Juliet Gallagher
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC...
05/28/2025
First Report Managed Care
Conference Coverage
Administrative Health Claims Data Study Highlights Demographics of Patients With Multiple Sclerosis in the US
05/31/2024
Grace Taylor, MS, MA
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights demographic data on subpopulations of people with multiple sclerosis (MS) in the US based on findings from administrative health claims (AHC) data sets.
A new study highlights...
05/31/2024
First Report Managed Care
Conference Coverage
Improvements in Patient-Reported Outcomes for Patients With MS Switching to Diroximel Fumarate
05/31/2024
Hannah Musick
This study aims to characterize patient-reported outcomes in individuals with multiple sclerosis (MS) who switched to diroximel fumarate (DRF), showing promising results in symptom severity and disability after 1 year of treatment.
This study aims to characterize patient-reported outcomes in individuals with multiple sclerosis (MS) who switched to diroximel fumarate (DRF), showing promising results in symptom severity and disability after 1 year of treatment.
This study aims to characterize...
05/31/2024
First Report Managed Care
News
Patient Diagnosed With Clinically Isolated Syndrome After Traumatic Brain Injury: Case Study
05/30/2024
Grace Taylor, MS, MA
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case...
05/30/2024
First Report Managed Care
Conference Coverage
Patient Receives Intravenous Immunoglobulin for Misdiagnosed Multiple Sclerosis: Case Study
05/29/2024
Grace Taylor, MS, MA
Researchers present a case study of a 53-year-old woman who was misdiagnosed with multiple sclerosis (MS) and experienced adverse effects after receiving the immunotherapy intravenous immunoglobulin (IVIG).
Researchers present a case study of a 53-year-old woman who was misdiagnosed with multiple sclerosis (MS) and experienced adverse effects after receiving the immunotherapy intravenous immunoglobulin (IVIG).
Researchers present a case study...
05/29/2024
First Report Managed Care
News
Using Mindfulness-Based Intervention to Improve Fatigue, Mood Challenges in Adolescents With Neuroimmune Disease
05/28/2024
Grace Taylor, MS, MA
Study examines the effectiveness of the Learning to BREATHE mindfulness-based intervention in improving fatigue and mood challenges in a adolescent population with neuroimmune disease.
Study examines the effectiveness of the Learning to BREATHE mindfulness-based intervention in improving fatigue and mood challenges in a adolescent population with neuroimmune disease.
Study examines the effectiveness...
05/28/2024
First Report Managed Care
News
Patients With MS on Ocrelizumab and Rituximab May Have Higher Risk of SARS-CoV-2 Infection Compared to Ofatumumab
05/28/2024
Hannah Musick
Recent research found that patients on ocrelizumab and rituximab are at a higher risk of contracting SARS-CoV-2 despite being vaccinated, compared to those on ofatumumab.
Recent research found that patients on ocrelizumab and rituximab are at a higher risk of contracting SARS-CoV-2 despite being vaccinated, compared to those on ofatumumab.
Recent research found that...
05/28/2024
First Report Managed Care
Conference Coverage
Immune Colitis Associated With Rituximab Therapy in Relapsing Multiple Sclerosis
05/24/2024
Hannah Musick
A case study highlighted rare immune colitis associated with rituximab therapy in a patient with relapsing multiple sclerosis (RMS) and emphasizes the need for increased awareness and monitoring of this potential adverse effect in clinical...
A case study highlighted rare immune colitis associated with rituximab therapy in a patient with relapsing multiple sclerosis (RMS) and emphasizes the need for increased awareness and monitoring of this potential adverse effect in clinical...
A case study highlighted rare...
05/24/2024
First Report Managed Care
Conference Coverage
The Impact of Dietary Interventions on Inflammatory Biomarkers in Adults With MS
05/24/2024
Hannah Musick
A systematic review of dietary interventions in adults with multiple sclerosis (MS) reveals potential positive effects on inflammatory biomarkers, offering hope for managing inflammation in MS patients.
A systematic review of dietary interventions in adults with multiple sclerosis (MS) reveals potential positive effects on inflammatory biomarkers, offering hope for managing inflammation in MS patients.
A systematic review of dietary...
05/24/2024
First Report Managed Care
Conference Coverage
The Impact of Fatigue on Prospective Memory in Persons With MS
05/23/2024
Hannah Musick
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons with multiple sclerosis (MS) are significantly associated with subjective impairment in prospective memory, particularly in tasks such as forgetting the date and missing appointments.
High fatigue levels in persons...
05/23/2024
First Report Managed Care
Conference Coverage
Monoclonal Antibody Reduces MS-Related Health Care Utilization
05/23/2024
Hannah Musick
Real-world data suggests that ofatumumab (OMB) may lead to a decrease in multiple sclerosis-related health care resource utilization, providing potential benefits for patients and health care systems.
Real-world data suggests that ofatumumab (OMB) may lead to a decrease in multiple sclerosis-related health care resource utilization, providing potential benefits for patients and health care systems.
Real-world data suggests that...
05/23/2024
First Report Managed Care
Conference Coverage
Addressing Suicidal Ideation in Persons With Multiple Sclerosis: Developing a Predictive Nomogram
05/22/2024
Hannah Musick
New research explored the development of a predictive nomogram to identify persons with multiple sclerosis at higher risk of suicidal ideation, emphasizing the importance of behavioral risk factors in this vulnerable population.
New research explored the development of a predictive nomogram to identify persons with multiple sclerosis at higher risk of suicidal ideation, emphasizing the importance of behavioral risk factors in this vulnerable population.
New research explored the...
05/22/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use